Aspirin for Heart Disease Prevention in Men: What the Trials Decided

Aspirin’s role in cardiovascular medicine has contracted significantly over the past decade. For secondary prevention, men with established coronary artery disease, prior MI, prior stroke, or prior revascularization, aspirin’s benefit remains well-established and the evidence is unambiguous. For primary prevention, men without established cardiovascular disease, three large modern trials have changed the calculus. The benefit of aspirin in reducing cardiovascular events is real but modest, the bleeding risk is real and age-dependent, and the net benefit is now judged insufficient in most men to recommend aspirin without established disease.

This shift is not a small refinement. For the better part of three decades, aspirin was recommended widely for primary prevention, and many men took it based on physician guidance that reflected the best available evidence at the time. What changed is that the evidence improved. Larger, better-designed trials with longer follow-up produced a more complete picture, one where aspirin’s bleeding cost came into clearer focus, where absolute event reductions proved smaller than initially estimated, and where the population of men who genuinely benefit became narrower and better defined.

Understanding this evolution requires going back to the trial that started it, examining what the modern trials found, and working through the risk-benefit math that now governs clinical decision-making.

The Foundational Data: Physicians’ Health Study

The Physicians’ Health Study (PHS) was the landmark trial that initially established aspirin’s cardiovascular benefit in men. It enrolled 22,071 US male physicians and randomized them to aspirin 325mg every other day versus placebo, with a median follow-up of approximately five years. The results were published in the New England Journal of Medicine in 1989.

The headline finding was striking: a 44% reduction in the risk of first myocardial infarction in the aspirin group (relative risk 0.56, 95% CI 0.45 to 0.70). 5 / Solid That result drove aspirin into widespread primary prevention use for men and shaped cardiology guidelines for years.

But there were critical nuances in the PHS data that deserved more attention than they initially received. There was no statistically significant reduction in cardiovascular mortality. The total stroke count did not favor aspirin, and there was a numerical trend toward increased hemorrhagic stroke in the aspirin group. The trial was also conducted in a relatively low-risk population, male physicians, predominantly healthy, predominantly white, whose characteristics may not translate to the broader population.

This sex-differentiated pattern within PHS is now recognized as the male aspirin signature: MI reduction without a corresponding reduction in stroke or cardiovascular death, accompanied by a hemorrhagic stroke signal. Subsequent trials confirmed this pattern and eventually made it impossible to ignore. The signal that PHS detected but could not fully quantify, that aspirin’s harms were real and would become more visible in larger and more diverse populations, turned out to be accurate.

The Modern Trials That Changed Guidance

Three large randomized controlled trials published in 2018 fundamentally altered how physicians think about aspirin for primary prevention. Each addressed a different population; together, they covered a broad swath of the men previously considered aspirin candidates.

ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) enrolled 12,546 men and women at moderate cardiovascular risk, defined as a 10-year risk between approximately 10% and 20%. Participants received aspirin 100mg per day or placebo for a median follow-up of five years. The composite outcome of major adverse cardiovascular events showed no statistically significant reduction in the aspirin group. Major gastrointestinal bleeding, however, was approximately double in the aspirin arm compared to placebo. 5 / Solid This trial was powered on the assumption that the enrolled population would have cardiovascular event rates consistent with their estimated 10-year risk, but the observed event rates were lower than predicted, which reduced the statistical power to detect a benefit. This is itself a meaningful finding: the men enrolled, despite appearing to be at moderate risk by calculator, had lower real-world event rates, possibly because statin use and other risk factor management reduced background event rates more than the models anticipated.

ASCEND (A Study of Cardiovascular Events in Diabetes) took a different approach and enrolled 15,480 patients with type 2 diabetes who did not have established cardiovascular disease. These patients received aspirin 100mg per day or placebo, followed for a median of 7.4 years. The aspirin group showed a 12% relative reduction in serious vascular events, which reached statistical significance. However, this was offset by an equivalent absolute increase in major bleeding events. The net clinical benefit across the overall population was approximately zero. 5 / Solid Diabetic men had long been considered strong candidates for aspirin primary prevention given their elevated cardiovascular risk; ASCEND substantially weakened that assumption.

ASPREE (Aspirin in Reducing Events in the Elderly) was perhaps the most consequential for redefining aspirin’s role in older men. It enrolled 19,114 healthy older adults, aged 70 or older in the United States, and 65 or older for Black and Hispanic participants, with a lower age threshold for underrepresented groups to reflect their higher baseline cardiovascular risk. Participants had no cardiovascular disease, dementia, or physical disability at baseline. The primary endpoint was disability-free survival. Aspirin 100mg per day did not improve disability-free survival compared to placebo. Major hemorrhage was significantly increased in the aspirin group. There was also an unexpected numerical excess in cancer mortality in the aspirin group that generated considerable discussion, though the mechanism and causal relationship remain under investigation. 5 / Solid

For older men specifically, ASPREE delivered a clear verdict: the bleeding risk in men aged 70 and above who do not have established cardiovascular disease outweighs any plausible cardiovascular benefit. Intracranial hemorrhage risk in older men with hypertension, which is common in this age group, can approach or exceed the MI risk reduction aspirin might provide.

Why Bleeding Risk Dominates in Primary Prevention

Aspirin’s mechanism is nonselective inhibition of cyclooxygenase-1 (COX-1), which irreversibly acetylates the enzyme and prevents platelets from producing thromboxane A2. Because platelets cannot synthesize new COX-1, they lack nuclei, a single dose of aspirin inhibits a platelet for its entire lifespan of approximately 7 to 10 days. This permanent antiplatelet effect is aspirin’s therapeutic strength in preventing arterial thrombosis. It is also the mechanism underlying every aspirin-associated bleeding complication.

Gastrointestinal bleeding represents aspirin’s most common serious harm. Aspirin damages the gastric mucosa through two pathways: direct topical irritation and systemic suppression of prostaglandin-mediated mucosal defense. Even doses as low as 75mg per day increase gastrointestinal bleeding risk approximately 1.5 to 2 times compared to placebo. The absolute risk is relatively low in young, otherwise healthy men, but it increases substantially with age, concurrent NSAID use, H. pylori infection, prior peptic ulcer disease, and heavy alcohol consumption. For a 68-year-old man who drinks regularly and takes ibuprofen occasionally for back pain, the annual absolute risk of a major GI bleed on aspirin is meaningfully higher than for a 48-year-old man with none of these risk factors.

Intracranial hemorrhage is the more catastrophic aspirin-associated bleeding complication. Aspirin increases bleeding from cerebral vessels, which matters most in older men who commonly have hypertension, cerebral amyloid angiopathy, and age-related vessel fragility. In men with controlled hypertension and no established cardiovascular disease, the incremental risk of hemorrhagic stroke from aspirin can approach or exceed the absolute risk reduction from prevented ischemic MI. This is the core of the ASPREE finding in older men: the bleed side of the equation simply outweighs the clot side.

The net benefit calculation shifts with age and baseline risk. A 52-year-old man with a 15% 10-year cardiovascular risk and no bleeding risk factors has a higher absolute event rate, a longer prevention horizon, and lower absolute bleeding risk than a 72-year-old man at 12% 10-year risk who takes NSAIDs and has a prior history of gastric ulcer. The same percentage risk reduction by aspirin produces a larger absolute benefit in the younger, higher-risk man and a smaller benefit in the older man with bleeding complicators. The arithmetic of primary prevention is fundamentally about absolute risk, not relative risk.

Current Guideline Position

The 2022 United States Preventive Services Task Force (USPSTF) recommendations represent the current synthesis of this evidence. The USPSTF recommends against initiating aspirin for primary cardiovascular disease prevention in adults aged 60 years and older, rating this as a Grade D recommendation (harm outweighs benefit). For adults aged 40 to 59 with a 10-year cardiovascular disease risk of 10% or greater, the USPSTF assigns a Grade C recommendation, meaning the net benefit is small and the decision should be individualized based on patient values and bleeding risk factors.

The 2019 American College of Cardiology and American Heart Association prevention guidelines took a similar position: low-dose aspirin might be considered for select higher-risk patients aged 40 to 70 who are not at increased bleeding risk; aspirin should not routinely be used for primary prevention in adults over 70. These guidelines specifically state that aspirin use for primary prevention should not be a routine recommendation and should involve shared decision-making that explicitly addresses bleeding risk.

This represents a significant retreat from the 2002 to 2010 era, when aspirin for primary prevention was recommended by multiple professional societies based substantially on PHS and on meta-analyses that included older, smaller trials with less rigorous bleeding outcome assessment. The modern trials generated more complete data and the guidance followed.

Who Retains a Strong Indication

Secondary prevention remains a substantial and uncontested indication. Men with established cardiovascular disease, prior myocardial infarction, coronary artery disease on angiography, prior coronary revascularization (PCI or CABG), stable angina, prior ischemic stroke or transient ischemic attack attributable to atherosclerosis, or symptomatic peripheral artery disease, should be on aspirin 75 to 100mg per day as a Class I recommendation. The evidence base for secondary prevention is entirely different from primary prevention in both magnitude and consistency.

Acute coronary syndrome is an unambiguous indication for aspirin loading. Standard of care for suspected ACS includes aspirin 325mg as soon as the diagnosis is considered, typically before coronary angiography. The antiplatelet effect in the acute setting is time-critical.

Men with peripheral artery disease and established symptomatic disease have evidence supporting aspirin use, though the benefit-risk calculation is more nuanced in asymptomatic PAD, where some guidelines have moved toward a more individualized approach.

For high-risk primary prevention with specific risk concentrations, some cardiologists will engage in individualized aspirin discussions. A 54-year-old man with a 20-pack-year smoking history, type 2 diabetes, LDL of 175 mg/dL despite statin therapy, and a calculated 10-year risk of 19% presents a different risk-benefit profile than the average primary prevention candidate. Evidence does not definitively resolve these edge cases; clinical judgment, patient preference, and bleeding risk assessment inform the decision.

Aspirin Resistance and Pharmacological Variability

Approximately 20 to 30% of patients show what is termed aspirin resistance, meaning inadequate platelet inhibition despite regular aspirin use. This phenomenon has several proposed mechanisms. COX-1 polymorphisms affect aspirin’s binding efficiency. Insufficient dosing, which is a theoretical concern at the very low doses used clinically, may leave some COX-1 uninhibited. Drug interactions are a common practical source of resistance: ibuprofen and other nonselective NSAIDs compete with aspirin for the COX-1 binding site and must not be taken within approximately eight hours of aspirin if antiplatelet efficacy is to be maintained. High platelet turnover states, including active smoking, poorly controlled diabetes, and certain inflammatory conditions, may partially offset aspirin’s effect because newly produced platelets replace inhibited ones more rapidly.

Aspirin resistance cannot be routinely assessed in clinical practice. Platelet function testing (VerifyNow, Multiplate) is used in select research and clinical settings, primarily to assess aspirin response after ACS or stent placement, but it is not standard of care for primary prevention monitoring.

The formulation of aspirin also matters pharmacologically. Enteric-coated aspirin, which is sold widely as the “stomach-friendly” option, delays absorption from the small intestine rather than the stomach. Some pharmacokinetic data show that this delayed and incomplete absorption may reduce peak plasma aspirin concentrations and consequently reduce antiplatelet efficacy, particularly for the first dose. For men taking aspirin for antiplatelet purposes rather than analgesia, plain (non-enteric-coated) aspirin may be pharmacologically preferable, even though it is associated with somewhat more gastric irritation. Men who use enteric-coated aspirin solely to reduce GI symptoms should be aware that the formulation choice has potential implications for the antiplatelet effect.

The Statin Alternative Framework

For men in the moderate cardiovascular risk range where aspirin used to be routinely recommended, statins now represent a far better-evidenced primary prevention intervention with a substantially more favorable benefit-harm profile. Statins reduce cardiovascular events through LDL lowering and pleiotropic anti-inflammatory effects. They do not increase bleeding risk. The evidence base includes multiple large randomized trials with consistent cardiovascular benefit across diverse populations.

The JUPITER trial, which enrolled patients with low-to-normal LDL but elevated high-sensitivity C-reactive protein, demonstrated substantial statin benefit in a population that would not previously have been considered for statin therapy by LDL thresholds alone. This expanded the population of men who may benefit from statin primary prevention considerably.

The clinical calculus for a man at 10 to 15% 10-year risk has shifted: the first question is no longer whether to add aspirin to lifestyle modification but whether to add or improve statin therapy. If a man is not on a statin, that is the higher-priority intervention. If he is on a statin, the bleeding-adjusted benefit of adding aspirin requires careful individual assessment and does not default to yes.

Synthesis

The trajectory of aspirin in primary prevention for men follows an arc familiar in evidence-based medicine: early enthusiasm based on dramatic relative risk reductions in a specific population, followed by refinement as trials expanded to broader populations with longer follow-up and better harm assessment. The 44% relative MI reduction in PHS was real in the population studied, but it translated into a smaller absolute benefit than anticipated, and the bleeding risk that seemed acceptable in a low-baseline-risk cohort of male physicians proved to be a meaningful harm signal when extended to older and more comorbid populations.

What has not changed is aspirin’s role in secondary prevention. Men with established cardiovascular disease are a fundamentally different group: their absolute event rate is higher, their baseline ischemic risk justifies the antiplatelet risk, and the evidence base is consistent across multiple trials and meta-analyses. For these men, aspirin remains a cornerstone of therapy.

For primary prevention, the current evidence supports a more selective approach. Men under 60 with high calculated cardiovascular risk and low bleeding risk may engage in a shared decision-making conversation with their physician. Men over 60 without established disease should not initiate aspirin for primary prevention based on current guidance. Men who are currently taking aspirin for primary prevention based on older guidance should have their situation reassessed.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.